

**Rating: Subscribe**

**Issue Offer**

Total issue size: INR 8,950 Mn (15.09 Mn shares) - OFS of INR 8,000 Mn (13.49 Mn shares) and a Fresh Issue of INR 950 Mn (1.60 Mn shares).

**Issue Summary**

Price Band (INR)	563-593
Face Value (INR)	1
Implied Market Cap (INR mn)	66,978
Market Lot	25
Issue Opens on	21 November, 2025
Issue Close on	25 November, 2025
No. of share pre-issue	11,13,46,602
No. of share post issue	11,29,48,626
Listing	NSE / BSE

**Issue Break-up (%)**

QIB Portion	≤50
NIB Portion	≥15
Retail Portion	≥35

**Book Running Lead Managers**

ICICI Securities Ltd

**Registrar**

MUFG Intime India Ltd

**Shareholding Pattern**

	Pre-Issue	Post-Issue
Promoters	89.36%	76.15%
Public & Others	10.60%	23.85%

**Objects of the issue**

Exp. Amt (INR Mn.)

Capital expenditure towards procurement of machinery for the production line located at Nandesari Facility I

758.1

General Corporate Purposes

**Abhishek Jain**

[abhishek.jain@arihantcapital.com](mailto:abhishek.jain@arihantcapital.com)

022-67114871

**Heli Shah**

[heli.shah@arihantcapital.com](mailto:heli.shah@arihantcapital.com)

022-67114873

Sudeep Pharma is a leading manufacturer of mineral-based nutritional ingredients with a strong presence across global pharma, food, and nutraceutical markets. Backed by deep technical expertise, a diversified product portfolio, and a growing international footprint, the company is well-positioned to benefit from rising demand for fortified foods, clinical nutrition, and specialty mineral blends. Its scaled manufacturing infrastructure, proprietary technologies, and expanding customer reach provide a solid foundation for sustained growth, margin expansion, and increasing relevance in the global vitamins and minerals value chain.

**Investment Rationale:**

**Leadership in High-Growth Nutritional Ingredients:** Sudeep Pharma is a leading player in the fast-growing nutritional ingredients market, especially in phosphates and iron-based minerals used in food fortification, infant nutrition, and clinical nutrition. With a large manufacturing base of 65,579 MT, it is among the biggest producers of food-grade Iron Phosphate. Its strong technical expertise and deep understanding of mineral chemistry allow it to meet strict global quality standards, creating high customer stickiness and a differentiated position across oxides, carbonates, sulphates, phosphates, gluconates, and specialty blends.

**Scaled, Compliant Manufacturing Infrastructure:** Company has a broad manufacturing base with three operational facilities and a fourth (NSS) added in FY25, plus a new unit coming up in Q4 FY26 for phosphates, gluconates, glycinates, and citrates. Current utilization levels—60%, 50%, and ~29% across key plants—offer ample room for growth as volumes ramp up. Its compliant, globally certified facilities enable scalability and support expansion into regulated international markets, strengthening long-term volume visibility.

**Robust Global Customer Base and Technological Edge:** Sudeep Pharma's presence across Europe, the USA, and India gives it diversified revenues and strong access to regulated markets. The acquisition of Nutrition Supplies Services (Ireland) Ltd further improves its formulation capabilities and regulatory strength. Its proprietary technologies—especially in encapsulation and liposomal nutrients—enhance absorption and support premium applications in clinical and infant nutrition. These advanced capabilities create strong differentiation, pricing power, and meaningful entry barriers. should drive better mix and margins.

**Valuation & Outlook:** Sudeep Pharma is set for steady multi-year growth supported by rising global demand for fortified nutrition, strong positions in phosphates and iron-based minerals, and upcoming capacity additions in FY26. Low current plant utilizations provide room for operating leverage, while its expanding presence in regulated markets and proprietary technologies ed to deliver healthy volume growth and gradual profitability improvement over the medium term. **At the upper band of INR 593, the issue is valued at a P/E ratio of 48x, based on annualized PAT of FY25 EPS of INR 12.3. OFS of INR 8,000 Mn (13.49 Mn shares) and a Fresh Issue of INR 950 Mn (1.60 Mn shares). We are recommending a "Subscribe" rating for this issue.**

**Financial Information:**

Particulars (INR Mn)	FY23	FY24	FY25
Revenue	4,383	4,654	5,113
<i>Growth (% YoY)</i>		6%	10%
EBITDA	986	1,878	1,992
<i>Margins (%)</i>	23%	40%	39%
PAT	623	1,332	1,387
<i>Margins (%)</i>	14%	29%	5%
Debt	823	750	1,353

**Arihant Research Desk**Email: [instresearch@arihantcapital.com](mailto:instresearch@arihantcapital.com)

Tel. : 022-42254800

Head Office	Registered Office
#1011, Solitaire Corporate Park Building No. 10, 1 <sup>st</sup> Floor Andheri Ghatkopar Link Road Chakala, Andheri (E) Mumbai – 400093 Tel: (91-22) 42254800 Fax: (91-22) 42254880	Arihant House E-5 Ratlam Kothi Indore - 452003, (M.P.) Tel: (91-731) 3016100 Fax: (91-731) 3016199

Stock Rating Scale	Absolute Return
BUY	>20%
ACCUMULATE	12% to 20%
HOLD	5% to 12%
NEUTRAL	-5% to 5%
REDUCE	-5% to -12%
SELL	<-12%

Research Analyst Registration No.	Contact	Website	Email Id
INH000002764	SMS: 'Arihant' to 56677	<a href="http://www.arihantcapital.com">www.arihantcapital.com</a>	<a href="mailto:instresearch@arihantcapital.com">instresearch@arihantcapital.com</a>

**Disclaimer:** This document has been prepared by Arihant Capital Markets Ltd. This document does not constitute an offer or solicitation for the purchase and sale of any financial instrument by Arihant. This document has been prepared and issued on the basis of publicly available information, internally developed data and other sources believed to be reliable. Whilst meticulous care has been taken to ensure that the facts stated are accurate and opinions given are fair and reasonable, neither the analyst nor any employee of our company is in any way is responsible for its contents and nor is its accuracy or completeness guaranteed. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Arihant may trade in investments, which are the subject of this document or in related investments and may have acted upon or used the information contained in this document or the research or the analysis on which it is based, before its publication. This is just a suggestion and Arihant will not be responsible for any profit or loss arising out of the decision taken by the reader of this document. Affiliates of Arihant may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. No matter contained in this document may be reproduced or copied without the consent of the firm.

Arihant Capital Markets Ltd.  
1011, Solitaire Corporate park, Building No. 10, 1st Floor,  
Andheri Ghatkopar Link Road, Chakala, Andheri (E)  
Tel. 022-42254800 Fax. 022-42254880

**Disclaimer:** This disclosure statement is provided in compliance with the SEBI Research Analyst Regulations, 2014. Arihant Capital Markets Limited (ACML) is a registered stockbroker, merchant banker, and research analyst under SEBI, and is also a Point of Presence with the Pension Fund Regulatory and Development Authority (PFRDA). ACML is registered with SEBI with Research Analyst Registration Number INH000002764, Stock Broker Registration Number INZ000180939, and is a Trading Member with NSE, BSE, MCX, NCDEX, and a Depository Participant with CDSL and NSDL.

ACML and its associates may have business relationships, including investment banking, with companies covered by its Investment Research Department. The analysts of ACML, and their associates, are prohibited from holding a financial interest in securities or derivatives of companies they cover, though they may hold stock in the companies they analyze. The recommendations provided by ACML's research team are based on technical and derivative analysis and may differ from fundamental research reports.

ACML confirms that neither it nor its associates have a financial interest or material conflict concerning the companies covered in the research report at the time of publication. Furthermore, ACML, its analysts, and their relatives have no ownership greater than 1% in the subject companies as of the month prior to publication. ACML guarantees that the compensation for its research analysts is not influenced by specific securities or transactions.

ACML affirms that neither the analyst nor the company has served as an officer, director, employee, or engaged in market-making activities for any of the subject companies. Additionally, the research report does not reflect any conflict of interest and is not influenced by specific recommendations made. Neither ACML nor its analysts have received compensation for investment banking or brokerage services from the subject companies in the last 12 months.

The views expressed in this report are those of the analysts and are independent of the proprietary trading desk of ACML, which operates separately to maintain an unbiased stance. Analysts comply with SEBI Regulations when offering recommendations or opinions through public media. The report is intended for informational purposes only and is not an offer or solicitation for the purchase or sale of securities.

This report, which is confidential, may not be reproduced or shared without written consent from ACML. It is based on publicly available data believed to be reliable but has not been independently verified, and no guarantees are made about its accuracy. All opinions and information contained in the report are subject to change without notice. ACML disclaims liability for any losses resulting from reliance on this report. The report does not constitute an offer to buy or sell securities, and ACML is not responsible for the risks involved in investments. ACML and its affiliates may have positions in the securities discussed or hold other financial interests in them.

The distribution of this report in certain jurisdictions may be restricted by law, and the report is not intended for distribution where it would violate local laws. Investors are advised to consider their financial position, risk tolerance, and investment objectives before engaging in transactions, particularly in high-risk financial products such as derivatives.

ACML reserves the right to modify this disclosure statement without prior notice. The report has been prepared using publicly available information and internally developed data, though ACML does not guarantee its completeness or accuracy. Historical price data for securities can be accessed via official exchanges like NSE or BSE. ACML and its affiliates may conduct proprietary transactions or investment banking services for the companies mentioned in this report. In compliance with SEBI regulations, ACML maintains comprehensive records of research reports, recommendations, and the rationale for those recommendations, which are preserved for at least five years. An annual compliance audit is conducted by a member of the ICAI or ICSI to ensure adherence to applicable regulations. This report is issued in accordance with applicable SEBI regulations and does not guarantee future performance or returns.